Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Natural Killer/T-cell Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NK/T-Cell Lymphoma
Overview
This is a multicenter prospective study to develop and validate a multimodal, deep learning-based model for predicting treatment response in patients with extranodal natural killer/T-cell lymphoma (NKTCL) receiving first-line asparaginase-based therapy.
Primary outcome measures
- Predictive accuracy of first-line treatment response (CR vs non-CR) according to Lugano 2014 criteria [Time frame: From baseline to disease response and follow-up assessments, up to 3 years.]
Eligibility criteria
Inclusion criteria
- 1\. Age ≥ 18 years.
- 2\. Pathologically confirmed extranodal natural killer/T-cell lymphoma (NKTCL) according to the World Health Organization (WHO) classification.
- 3\. Patients who are planned to receive first-line asparaginase-based chemotherapy or chemoradiotherapy.
- 4\. Patients who have either contrast-enhanced MRI of the nasopharynx obtained as part of routine clinical care or pretreatment whole-slide images (WSI) of tumor tissue from hematoxylin and eosin (H\&E)-stained sections available for analysis.
- 5\. Ability to understand the study and provide written informed consent (ICF).
Exclusion criteria
- 1\. History of other malignant tumors.
- 2\. Patients with psychiatric disorders or those unable to provide informed consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07409168 · B2025-444